{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:19:02Z","timestamp":1789957142434,"version":"4.0.1"},"reference-count":144,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Generalized pustular psoriasis (GPP) is a severe, relapsing, immune-mediated disease characterized by the presence of multiple sterile pustules all over the body. The exact pathomechanisms behind GPP remain elusive, although increased interest in the genetic basis and immunological disturbances have provided some revealing insights into the underlying signaling pathways and their mutual interaction. The genetic background of GPP has been thoroughly investigated over the past few years. The conducted studies have identified genetic variants that predispose to pustular forms of psoriasis. The loss-of-function mutation of the interleukin 36 receptor antagonist gene, along with rare gain-of-function mutations in the gene that encodes the keratinocyte signaling molecule (CARD14), are examples of the uncovered abnormalities. Interleukin 36 (IL-36), along with neutrophils, is now considered a central cytokine in GPP pathogenesis, with IL-36 signaling providing a link between innate and adaptive immune responses. More recently, a new concept of inflammation, caused by a predominantly genetically determined abnormal activation of innate immune response and leading to inflammatory keratinization, has arisen. GPP is currently considered a representative of this novel group of skin conditions, called autoinflammatory keratinization diseases. As no therapeutic agents have been approved for GPP to date in the United States and Europe, the novel anti-IL-36R antibodies are particularly promising and may revolutionize management of the disease.<\/jats:p>","DOI":"10.3390\/ijms22169048","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T21:47:52Z","timestamp":1629668872000},"page":"9048","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity"],"prefix":"10.3390","volume":"22","author":[{"given":"Dominik","family":"Samotij","sequence":"first","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University ul. Fryderyka Szopena 2, 35-055 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Szcz\u0119ch","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University ul. Fryderyka Szopena 2, 35-055 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"Adam","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University ul. Fryderyka Szopena 2, 35-055 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2133.1968.tb11947.x","article-title":"Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases","volume":"80","author":"Baker","year":"1968","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2133.1971.tb14044.x","article-title":"The prognosis of generalized pustular psoriasis","volume":"85","author":"Ryan","year":"1971","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/archderm.1991.01680080075005","article-title":"Generalized pustular psoriasis. A review of 63 cases","volume":"127","author":"Zelickson","year":"1991","journal-title":"Arch. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2340\/00015555766871","article-title":"Generalized pustular psoriasis in Japan: Two distinct groups formed by differences in symptoms and genetic background","volume":"76","author":"Ohkawara","year":"1996","journal-title":"Acta Derm. Venereol."},{"key":"ref_5","first-page":"669","article-title":"Generalized pustular psoriasis (Zumbusch): A French epidemiological survey","volume":"16","author":"Augey","year":"2006","journal-title":"Eur. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/1346-8138.14105","article-title":"Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research","volume":"45","author":"Ito","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/j.1346-8138.2010.01145.x","article-title":"Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002\u20132008","volume":"38","author":"Takahashi","year":"2011","journal-title":"J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/1346-8138.12863","article-title":"Clinical features and course of generalized pustular psoriasis in Korea","volume":"42","author":"Jin","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: Epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Burns, T., Cox, N., and Griffiths, C. (2010). Psoriasis. Rook\u2019s Textbook of Dermatology, Wiley-Blackwell. [8th ed.].","DOI":"10.1002\/9781444317633"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/11586900-000000000-00000","article-title":"Clinical and laboratory features in acute generalized pustular psoriasis: A retrospective study of 34 patients","volume":"12","author":"Silva","year":"2011","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/hep.20305","article-title":"High frequency of cholestasis in generalized pustular psoriasis: Evidence for neutrophilic involvement of the biliary tract","volume":"40","author":"Viguier","year":"2004","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.16232","article-title":"Pustular psoriasis and related pustular skin diseases","volume":"178","author":"Bachelez","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: Analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s00403-002-0371-6","article-title":"Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity","volume":"295","author":"Umezawa","year":"2003","journal-title":"Arch. Dermatol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/1203475418758986","article-title":"Generalized Pustular Psoriasis Induced by Infliximab in a Patient with Inflammatory Bowel Disease","volume":"22","author":"Almutairi","year":"2018","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/09546634.2010.534430","article-title":"Flare of pustular psoriasis after initiating ustekinumab therapy","volume":"23","author":"Wenk","year":"2012","journal-title":"J. Dermatolog. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1600-0560.2010.01612.x","article-title":"The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis","volume":"37","author":"Kardaun","year":"2010","journal-title":"J. Cutan. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e11741","DOI":"10.1097\/MD.0000000000011741","article-title":"Genetic polymorphism of IL36RN in Han patients with generalized pustular psoriasis in Sichuan region of China: A case\u2013control study","volume":"97","author":"Li","year":"2018","journal-title":"Medicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1346-8138.1999.tb03444.x","article-title":"Treatments of generalized pustular psoriasis: A multicenter study in Japan","volume":"26","author":"Ozawa","year":"1999","journal-title":"J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/exd.13699","article-title":"Generalized pustular psoriasis\u2014A model disease for specific targeted immunotherapy, systematic review","volume":"27","author":"Boehner","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/1346-8138.13306","article-title":"Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study","volume":"43","author":"Imafuku","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/1346-8138.14523","article-title":"Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of Generalized Pustular Psoriasis. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP","volume":"45","author":"Fujita","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjd.14702","article-title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: Results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/1346-8138.14294","article-title":"Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study","volume":"45","author":"Sano","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","article-title":"Biologics in the treatment of pustular psoriasis","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3892\/ijmm.2021.4951","article-title":"An update on genetic basis of generalized pustular psoriasis (Review)","volume":"47","author":"Zhou","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1358\/dot.2019.55.9.3020159","article-title":"The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis","volume":"55","author":"Plachouri","year":"2019","journal-title":"Drugs Today"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An update on generalized pustular psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_35","first-page":"1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"9","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","article-title":"Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation","volume":"67","author":"Robinson","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-4632.2008.03954.x","article-title":"Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis\u2014A therapeutic challenge","volume":"47","author":"Kucharekova","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","article-title":"Psoriasis: A mixed autoimmune and autoinflammatory disease","volume":"49","author":"Liang","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2016.10.021","article-title":"Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders","volume":"139","author":"Liang","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/art.30588","article-title":"A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: Description of two unrelated cases from Brazil","volume":"63","author":"Jesus","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archdermatol.2011.3208","article-title":"Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis","volume":"148","author":"Minkis","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMoa0809568","article-title":"An autoinflammatory disease due to homozygous deletion of the IL1RN locus","volume":"360","author":"Reddy","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1525-1470.2012.01725.x","article-title":"Deficiency of interleukin-1 receptor antagonist responsive to anakinra","volume":"30","author":"Schnellbacher","year":"2013","journal-title":"Pediatr. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1084\/jem.20070157","article-title":"Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation","volume":"204","author":"Blumberg","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","article-title":"AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking","volume":"94","author":"Simpson","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production","volume":"136","author":"Mahil","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1038\/jid.2015.288","article-title":"Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris","volume":"135","author":"Berki","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjd.15867","article-title":"The genetic basis for most patients with pustular skin disease remains elusive","volume":"178","author":"Oji","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13677","DOI":"10.1074\/jbc.M400117200","article-title":"Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs","volume":"279","author":"Towne","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri2691","article-title":"The IL-1 family: Regulators of immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/imr.12610","article-title":"Regulation and function of interleukin-36 cytokines","volume":"281","author":"Bassoy","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/jid.2013.361","article-title":"IL36RN mutations in generalized pustular psoriasis: Just the tip of the iceberg?","volume":"133","author":"Capon","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/humu.22203","article-title":"Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis","volume":"34","author":"Farooq","year":"2013","journal-title":"Hum. Mutat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jaci.2017.05.019","article-title":"Autoinflammatory keratinization diseases","volume":"140","author":"Akiyama","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdermsci.2018.01.012","article-title":"Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin","volume":"90","author":"Akiyama","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fimmu.2020.00280","article-title":"Autoinflammatory Keratinization Diseases (AiKDs): Expansion of Disorders to Be Included","volume":"11","author":"Akiyama","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","article-title":"\u201cAutoinflammatory psoriasis\u201d\u2014genetics and biology of pustular psoriasis","volume":"18","author":"Uppala","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00403-015-1611-x","article-title":"Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients","volume":"308","author":"Wang","year":"2016","journal-title":"Arch. Dermatol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"adv00034","DOI":"10.2340\/00015555-3388","article-title":"Pustular Psoriasis: The Dawn of a New Era","volume":"100","author":"Bachelez","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial pityriasis rubra pilaris is caused by mutations in CARD14","volume":"91","author":"Sarig","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1600-065X.2008.00749.x","article-title":"CARMA1-mediated NF-kappaB and JNK activation in lymphocytes","volume":"228","author":"Blonska","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","article-title":"PSORS2 is due to mutations in CARD14","volume":"90","author":"Jordan","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40257-019-00492-0","article-title":"Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects","volume":"21","author":"Takeichi","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1096\/fj.201802090RR","article-title":"Neutrophil exosomes enhance the skin autoinflammation in generalized pustular psoriasis via activating keratinocytes","volume":"33","author":"Shao","year":"2019","journal-title":"FASEB J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/jid.2014.46","article-title":"CARD14 c.526G > C (pAsp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort","volume":"134","author":"Sugiura","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2016.3601","article-title":"Pityriasis Rubra Pilaris Type V as an Autoinflammatory Disease by CARD14 Mutations","volume":"153","author":"Takeichi","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-5793(03)00041-3","article-title":"Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1","volume":"536","author":"Heyninck","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/jid.2015.111","article-title":"Identification of Two Loci Associated with Generalized Pustular Psoriasis","volume":"135","author":"Zhang","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4103\/0366-6999.184470","article-title":"Tumor Necrosis Factor-alpha Induced Protein 3 Interacting Protein 1 Gene Polymorphisms and Pustular Psoriasis in Chinese Han Population","volume":"129","author":"Han","year":"2016","journal-title":"Chin. Med. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"23616","DOI":"10.1016\/S0021-9258(19)49507-0","article-title":"Antichymotrypsin interaction with chymotrypsin. Partitioning of the complex","volume":"268","author":"Cooperman","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jid.2019.11.024","article-title":"Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis","volume":"140","author":"Frey","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2147\/DDDT.S194765","article-title":"Cathepsin G cleaves and activates IL-36\u03b3 and promotes the inflammation of psoriasis","volume":"13","author":"Guo","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/10428199409049717","article-title":"Myeloperoxidase gene expression in normal granulopoiesis and acute leukemias","volume":"15","author":"Austin","year":"1994","journal-title":"Leuk. Lymphoma."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000246265","article-title":"Pustular psoriasis in a patient with myeloperoxidase deficiency","volume":"193","author":"Dominguez","year":"1996","journal-title":"Dermatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ajhg.2020.06.020","article-title":"Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease","volume":"107","author":"Vergnano","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood.V83.7.1935.1935","article-title":"Myeloperoxidase (MPO) gene mutation in hereditary MPO deficiency","volume":"83","author":"Kizaki","year":"1994","journal-title":"Blood"},{"key":"ref_85","first-page":"S10","article-title":"Genetic studies on myeloperoxidase deficiency in Italy","volume":"57","author":"Marchetti","year":"2004","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ajhg.2020.07.001","article-title":"Myeloperoxidase Modulates Inflammation in Generalized Pustular Psoriasis and Additional Rare Pustular Skin Diseases","volume":"107","author":"Haskamp","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-153-1-201007060-00030","article-title":"Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: Lack of correlation with IL1RN mutations","volume":"153","author":"Viguier","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjd.12548","article-title":"Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations","volume":"170","author":"Mohr","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful response in a case of severe pustular psoriasis after interleukin-1\u03b2 inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e043666","DOI":"10.1136\/bmjopen-2020-043666","article-title":"Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare","volume":"11","author":"Choon","year":"2021","journal-title":"BMJ Open"},{"key":"ref_93","unstructured":"ClinicalTrials.gov (2021, May 15). A 5-year Study to Test BI 655130 in Patients with Generalized Pustular Psoriasis Who Took Part in Previous Studies with BI 655130, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03886246."},{"key":"ref_94","unstructured":"ClinicalTrials.gov (2021, May 15). A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis (GPP), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619902."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","article-title":"Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"ref_96","first-page":"127","article-title":"The systemic autoinflammatory diseases: Inborn errors of the innate immune system","volume":"305","author":"Brydges","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: Implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1189\/jlb.3RI1014-495R","article-title":"Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions","volume":"97","author":"Gabay","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D33N39N8XM","article-title":"Interleukin-23 and interleukin-17: Importance in pathogenesis and therapy of psoriasis","volume":"18","author":"Mudigonda","year":"2012","journal-title":"Dermatol. Online J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and T cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e202000688","DOI":"10.26508\/lsa.202000688","article-title":"IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis","volume":"3","author":"Goldstein","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 Activity Promotes Clonal CD4+ T-Cell Responses with IL-17A Production in Generalized Pustular Psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/120347540400800404","article-title":"Successful treatment of Von Zumbusch pustular psoriasis with infliximab","volume":"8","author":"Trent","year":"2004","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2340\/00015555-2808","article-title":"Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis","volume":"98","author":"Furue","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/exd.14171","article-title":"Generalized pustular psoriasis-Dawn of a new era in targeted immunotherapy","volume":"29","author":"Neuhauser","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/jid.2013.404","article-title":"IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions","volume":"134","author":"Croxford","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"964069","DOI":"10.1155\/2014\/964069","article-title":"IL-6 as a druggable target in psoriasis: Focus on pustular variants","volume":"2014","author":"Saggini","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s13555-021-00493-0","article-title":"Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists","volume":"11","author":"Strober","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/dth.12325","article-title":"Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab","volume":"29","author":"Pan","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e12838","DOI":"10.1111\/dth.12838","article-title":"Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis: A case report","volume":"32","author":"Chen","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_118","first-page":"e13","article-title":"Childhood generalized pustular psoriasis: Longtime remission with combined infliximab and methotrexate treatment","volume":"32","author":"Weger","year":"2015","journal-title":"Pediatr. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/jdv.13388","article-title":"Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis","volume":"30","author":"Tsang","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/2013.jamadermatol.80","article-title":"Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis","volume":"148","author":"Viguier","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2133.2006.07639.x","article-title":"A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: Evidence for efficacy and high incidence of biological autoimmunity","volume":"156","author":"Poulalhon","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1346-8138.13632","article-title":"Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis","volume":"44","author":"Matsumoto","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14712598.2019.1555235","article-title":"Anti-IL17 therapies for psoriasis","volume":"19","author":"Paek","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/j.1365-2133.2010.09995.x","article-title":"Ustekinumab: Effective in a patient with severe recalcitrant generalized pustular psoriasis","volume":"163","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamadermatol.2016.0751","article-title":"Therapeutic Efficacy of Interleukin 12\/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status","volume":"152","author":"Arakawa","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/ced.12868","article-title":"Generalized pustular psoriasis treated with ustekinumab","volume":"41","author":"Storan","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-017-0800-7","article-title":"Guselkumab: First Global Approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","article-title":"Risankizumab: First Global Approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"ref_129","unstructured":"ClinicalTrials.gov (2021, May 12). A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects with Generalized Pustular Psoriasis or Erythrodermic Psoriasis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03022045."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1542\/peds.2012-3935","article-title":"First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra","volume":"132","author":"Piram","year":"2013","journal-title":"Pediatrics"},{"key":"ref_131","first-page":"755","article-title":"Gevokizumab, an anti-IL-1\u03b2 mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease","volume":"12","author":"Geiler","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1203475419888862","article-title":"Spesolimab: A Novel Treatment for Pustular Psoriasis","volume":"24","author":"Ratnarajah","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_133","unstructured":"(2021, April 08). AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP). AnaptysBio. News Release. Available online: https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptysbio-reports-positive-topline-data-gallop-phase-2-clinical."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/1346-8138.14664","article-title":"Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study","volume":"45","author":"Morita","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e13294","DOI":"10.1111\/dth.13294","article-title":"Childhood generalized pustular psoriasis: Successful long-term treatment with adalimumab","volume":"33","author":"Hansel","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/1346-8138.14636","article-title":"Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work","volume":"45","author":"Ho","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/1346-8138.15355","article-title":"Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol","volume":"47","author":"Mizutani","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/1203475418773358","article-title":"Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review","volume":"22","author":"Zhou","year":"2018","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e14814","DOI":"10.1111\/dth.14814","article-title":"Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study","volume":"34","author":"Kromer","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000346243","article-title":"Rapid downregulation of innate immune cells, interleukin-12 and interleukin-23 in generalized pustular psoriasis with infliximab in combination with acitretin","volume":"225","author":"Tang","year":"2012","journal-title":"Dermatology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2340\/0001555576357360","article-title":"Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: A comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1","volume":"76","author":"Zonneveld","year":"1996","journal-title":"Acta Dermatol. Venereol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1046\/j.1365-2133.2000.03878.x","article-title":"Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker)","volume":"143","author":"Salim","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_144","unstructured":"ClinicalTrials.gov (2021, May 16). A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-Ups in Patients with Generalized Pustular Psoriasis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04399837."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/9048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:49:10Z","timestamp":1760165350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/9048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,22]]},"references-count":144,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22169048"],"URL":"https:\/\/doi.org\/10.3390\/ijms22169048","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,22]]}}}